Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Provectus Biopharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.08M, down 53.2% year over year. For fiscal 2025 it was $1.90M, down 7.5% from the year before. Over ten years it grew -16.4% a year on average. The highest annual figure on record is $11.38M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90M | -7.5% |
| FY2024 | Dec 31, 2024 | $2.05M | +17.2% |
| FY2023 | Dec 31, 2023 | $1.75M | -26.8% |
| FY2022 | Dec 31, 2022 | $2.39M | -8.4% |
| FY2021 | Dec 31, 2021 | $2.61M | -7.3% |
| FY2020 | Dec 31, 2020 | $2.81M | -29.7% |
| FY2019 | Dec 31, 2019 | $4.00M | -15.7% |
| FY2018 | Dec 31, 2018 | $4.75M | -42.1% |
| FY2017 | Dec 31, 2017 | $8.20M | -0.1% |
| FY2016 | Dec 31, 2016 | $8.21M | -27.8% |
| FY2015 | Dec 31, 2015 | $11.38M | +95.9% |
| FY2014 | Dec 31, 2014 | $5.81M | +61.6% |
| FY2013 | Dec 31, 2013 | $3.60M | -28.2% |
| FY2012 | Dec 31, 2012 | $5.01M | -43.2% |
| FY2011 | Dec 31, 2011 | $8.81M | +4.6% |
| FY2010 | Dec 31, 2010 | $8.42M | +71.5% |
| FY2009 | Dec 31, 2009 | $4.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $131.13K | -85.1% |
| Q1 FY2026 | Mar 31, 2026 | $333.33K | -17.2% |
| Q4 FY2025 | Dec 31, 2025 | $268.43K | -55.9% |
| Q3 FY2025 | Sep 30, 2025 | $345.86K | -16.5% |
| Q2 FY2025 | Jun 30, 2025 | $880.84K | +86.3% |
| Q1 FY2025 | Mar 31, 2025 | $402.70K | -27.5% |
| Q4 FY2024 | Dec 31, 2024 | $608.21K | +46.3% |
| Q3 FY2024 | Sep 30, 2024 | $413.99K | +18.0% |
| Q2 FY2024 | Jun 30, 2024 | $472.93K | +8.9% |
| Q1 FY2024 | Mar 31, 2024 | $555.54K | +1.3% |
| Q4 FY2023 | Dec 31, 2023 | $415.84K | +29.5% |
| Q3 FY2023 | Sep 30, 2023 | $350.79K | -39.6% |
| Q2 FY2023 | Jun 30, 2023 | $434.21K | -46.8% |
| Q1 FY2023 | Mar 31, 2023 | $548.39K | -18.3% |
| Q4 FY2022 | Dec 31, 2022 | $321.21K | -56.7% |
| Q3 FY2022 | Sep 30, 2022 | $580.39K | -4.6% |
| Q2 FY2022 | Jun 30, 2022 | $816.65K | +35.4% |
| Q1 FY2022 | Mar 31, 2022 | $671.12K | +2.4% |
| Q4 FY2021 | Dec 31, 2021 | $741.58K | +37.5% |
| Q3 FY2021 | Sep 30, 2021 | $608.65K | -8.8% |
| Q2 FY2021 | Jun 30, 2021 | $602.98K | -13.4% |
| Q1 FY2021 | Mar 31, 2021 | $655.14K | -28.0% |
| Q4 FY2020 | Dec 31, 2020 | $539.34K | -28.3% |
| Q3 FY2020 | Sep 30, 2020 | $667.52K | -33.5% |
| Q2 FY2020 | Jun 30, 2020 | $696.45K | -42.4% |
| Q1 FY2020 | Mar 31, 2020 | $909.45K | -12.3% |
| Q4 FY2019 | Dec 31, 2019 | $751.91K | -41.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.00M | +90.1% |
| Q2 FY2019 | Jun 30, 2019 | $1.21M | +22.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.04M | -46.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.29M | -33.4% |
| Q3 FY2018 | Sep 30, 2018 | $528.36K | -76.6% |
| Q2 FY2018 | Jun 30, 2018 | $987.24K | -56.2% |
| Q1 FY2018 | Mar 31, 2018 | $1.94M | +10.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.94M | +44.7% |
| Q3 FY2017 | Sep 30, 2017 | $2.26M | -8.1% |
| Q2 FY2017 | Jun 30, 2017 | $2.25M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.75M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.34M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.46M | – |
See a number that looks wrong?